Beam Therapeutics (BEAM) Consolidated Net Income (2019 - 2026)

Beam Therapeutics (BEAM) has reported Consolidated Net Income for 8 consecutive years, with -$98.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income rose 10.25% year-over-year to -$98.3 million; the TTM figure through Mar 2026 stood at -$52.2 million (up 86.52% YoY), while the FY2025 annual figure was -$63.2 million, up 83.23% from the prior year.
• Consolidated Net Income retreated to -$98.3 million in Q1 2026 per BEAM's latest filing, from $261.1 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $261.1 million in Q4 2025 and bottomed at -$176.2 million in Q2 2022.
• Historically, Consolidated Net Income has averaged -$61.9 million across 5 years, with a median of -$92.7 million in 2024.
• Annual changes were most pronounced in 2022 — Consolidated Net Income slumped 199.01% — and 2023, when it soared 472.27%.
• Beam Therapeutics' Consolidated Net Income stood at -$38.3 million in 2022, then jumped by 472.27% to $142.8 million in 2023, then sank by 163.29% to -$90.4 million in 2024, then soared by 388.97% to $261.1 million in 2025, then plunged by 137.65% to -$98.3 million in 2026.
• Business Quant data shows BEAM's Consolidated Net Income at -$98.3 million in Q1 2026, $261.1 million in Q4 2025, and -$112.7 million in Q3 2025.